First-generation SHP2 inhibitors like TNO155 are currently under clinical evaluation (e.g., ClinicalTrials.gov identifier: NCT03114319); chordoma cells’ differential sensitivity to SHP2 suppression relative to other cancer types supports testing these inhibitors in chordoma patients. This evidence concerns the gene PTPN11 and cancer.